Export financials
Genetic Technologies Limited (GENE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Genetic Technologies Limited Cash Flow 2024-2011 | GENE
Brief cash flow overview of Genetic Technologies Limited
Cash flow changes are traced through the five latest available reports from 2020 to 2024.
Cash from operations is below zero at -9.7 million AUD, increasing dependence on cash reserves or outside financing.
Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.
What the cash flows show
Genetic Technologies Limited's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow Genetic Technologies Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-9.68 M | -9.72 M | -5.66 M | -6.3 M | -5.71 M | -6.07 M | -5.64 M | -6.85 M | -7.73 M | - | - | - | - | - |
All numbers in AUD currency
Quarterly Cash Flow Genetic Technologies Limited
| 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-9.68 M | -4.01 M | -9.72 M | -6.13 M | - | -5.66 M | - | - | - | -6.3 M | - | - | - | -5.71 M | - | - | - | -6.07 M | - | - | - | -5.64 M | - | - | - | -6.85 M | - | - | - | -7.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Cash Flow Statement is one of the three key financial reports of the company Genetic Technologies Limited, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
$ 2.81 | 1.63 % | $ 91.2 K | ||
|
Biodesix
BDSX
|
$ 27.49 | 1.95 % | $ 208 M | ||
|
Biomerica
BMRA
|
$ 2.4 | 5.96 % | $ 7 M | ||
|
BioNano Genomics
BNGO
|
$ 1.35 | 10.66 % | $ 7.35 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 11.67 | 5.68 % | $ 123 M | ||
|
Bioventus
BVS
|
$ 13.22 | 1.85 % | $ 881 M | ||
|
CareDx, Inc
CDNA
|
$ 52.37 | 4.21 % | $ 2.79 B | ||
|
Celcuity
CELC
|
$ 83.55 | 0.12 % | $ 3.91 B | ||
|
Co-Diagnostics
CODX
|
$ 1.14 | 1.79 % | $ 1.52 M | ||
|
Charles River Laboratories International
CRL
|
$ 269.48 | 0.06 % | $ 13.4 B | ||
|
Castle Biosciences
CSTL
|
$ 33.22 | 2.74 % | $ 963 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 239.32 | 1.83 % | $ 26.6 B | ||
|
Danaher Corporation
DHR
|
$ 202.7 | 1.28 % | $ 144 B | ||
|
DarioHealth Corp.
DRIO
|
$ 7.1 | 2.31 % | $ 28.3 M | ||
|
Fulgent Genetics
FLGT
|
$ 20.56 | 0.54 % | $ 633 M | ||
|
Guardant Health
GH
|
$ 165.87 | 5.39 % | $ 20.8 B | ||
|
ICON Public Limited Company
ICLR
|
$ 169.34 | 0.02 % | $ 13.3 B | ||
|
IDEXX Laboratories
IDXX
|
$ 509.72 | 0.99 % | $ 41 B | ||
|
Illumina
ILMN
|
$ 207.94 | 0.72 % | $ 32.2 B | ||
|
IQVIA Holdings
IQV
|
$ 264.81 | 1.16 % | $ 45.5 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 314.56 | 0.95 % | $ 26.2 B | ||
|
Lantheus Holdings
LNTH
|
$ 100.27 | 0.02 % | $ 6.77 B | ||
|
Medpace Holdings
MEDP
|
$ 591.17 | 0.62 % | $ 17.1 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 287.94 | 1.01 % | $ 26.5 B | ||
|
Myriad Genetics
MYGN
|
$ 3.74 | 9.36 % | $ 346 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 5.68 | 0.98 % | $ 4.47 M | ||
|
NeoGenomics
NEO
|
$ 18.27 | 5.51 % | $ 2.34 B | ||
|
Neogen Corporation
NEOG
|
$ 11.87 | 0.72 % | $ 2.58 B | ||
|
National Research Corporation
NRC
|
$ 22.14 | 4.83 % | $ 496 M | ||
|
Natera
NTRA
|
$ 339.13 | 3.1 % | $ 46.4 B | ||
|
OPKO Health
OPK
|
$ 1.55 | 0.38 % | $ 1.16 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.36 | 4.23 % | $ 408 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 25.15 | 2.28 % | $ 23.8 B | ||
|
Personalis
PSNL
|
$ 16.3 | 0.52 % | $ 1.45 B | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Senseonics Holdings
SENS
|
$ 8.88 | 1.95 % | $ 371 M | ||
|
Neuronetics
STIM
|
$ 2.89 | 5.61 % | $ 191 M | ||
|
Thermo Fisher Scientific
TMO
|
$ 611.62 | 0.3 % | $ 231 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Twist Bioscience Corporation
TWST
|
$ 136.05 | 6.94 % | $ 8.14 B | ||
|
VolitionRx Limited
VNRX
|
$ 0.31 | 0.34 % | $ 39 M | ||
|
Waters Corporation
WAT
|
$ 407.54 | 1.67 % | $ 24.3 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M |